Breaking Down Zhejiang Ausun Pharmaceutical Co., Ltd. Financial Health: Key Insights for Investors

Zhejiang Ausun Pharmaceutical Co., Ltd., a coastal pharmaceutical innovator founded in April 2010 and publicly traded under stock code 603229 since its Shanghai Stock Exchange listing on May 9, 2017, has grown into a research-driven manufacturer of preparations, specialty APIs and key intermediates that export to Europe, the US, Japan and South Korea; with nearly 800 employees and an R&D, development and analysis team of over 200 doctors and masters, the company has positioned R&D investment at more than 10% of operating income over the past three years-an investment philosophy reflected in its academician workstation, Zhejiang Provincial Research Institute and provincial enterprise technology center-discover how these mission, vision and core values of Integrity, Diligence, Pragmatism, Innovation and social responsibility are shaping its drive to become a first-class global pharmaceutical enterprise

Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS) - Intro

Mission

• Deliver high-quality, safe and affordable pharmaceutical solutions worldwide by advancing API and preparation R&D and scalable production.
• Support global health through targeted innovation in specialty APIs and intermediates used in critical therapies.
• Maintain compliant, sustainable manufacturing aligning with international regulatory standards to ensure export reliability.

Vision

• Become a globally recognized Chinese innovator in specialty APIs and formulation technologies, expanding market share in Europe, North America and Asia-Pacific.
• Achieve sustained growth by scaling proprietary processes, strengthening partnerships with academic institutions (leveraging the academician workstation), and increasing R&D commercialization.
• Evolve into an integrated pharma platform balancing upstream API leadership with downstream formulation capabilities to capture greater value across the supply chain.

Core Values

• Scientific Excellence - sustained investment in R&D (R&D talent >200) and academic collaboration to drive product quality and differentiation.
• Regulatory Integrity - rigorous compliance with GMP and export-oriented regulatory regimes to secure access to stringent markets.
• Customer Focus - delivering reliable supply and technical support to pharmaceutical partners in Europe, the US, Japan and Korea.
• Operational Discipline - continuous improvement of manufacturing efficiency and safety in the Toumengang chemical API base.
• Sustainability & Responsibility - minimizing environmental footprint in chemical API synthesis and committing to safe workplace practices.

Strategic KPIs & Operational Targets

Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS) - Overview

• Mission focus: develop innovative, high-quality medicines targeted at unmet clinical needs.
• Patient-centricity: prioritizing quality of life and therapeutic outcomes in R&D and product strategy.
• Strategic R&D commitment: sustained investment to translate research into clinical and commercial products.

• To be a leading developer of innovative pharmaceuticals that measurably improve patients' lives domestically and internationally.
• To build sustainable pipelines through translational research, strategic partnerships, and disciplined investment.

• Innovation: allocating resources and cultivating talent to transform science into therapies.
• Integrity: adherence to regulatory, clinical and ethical standards across development and commercialization.
• Quality: commitment to product safety, manufacturing excellence, and post-market vigilance.
• Collaboration: partnering with academic institutions, biotech peers, and healthcare stakeholders to accelerate development.
• Patient-first: prioritizing therapeutic benefit and life-quality outcomes in decision-making.

Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS) - Mission Statement

"We are committed to becoming a first-class enterprise in the global pharmaceutical and healthcare markets."

This vision encapsulates Zhejiang Ausun Pharmaceutical Co., Ltd.'s ambition for global recognition and sector leadership. By aspiring to be "first-class," the company sets a high bar for operational excellence, product safety and efficacy, and international competitiveness. The emphasis on global pharmaceutical and healthcare markets signals a strategic commitment to cross-border expansion, diversification of product channels, and heightened regulatory and quality standards aligned with leading global peers.

• Global ambition: targeted expansion into international markets with regulatory alignment and export growth.
• Operational excellence: adherence to high-quality manufacturing standards and continuous process improvement.
• Innovation-driven growth: sustained investment in R&D platforms and technology transfer to commercial products.

Structural commitments to realize this vision are evident in the company's R&D and innovation infrastructure. Key platforms created to underpin long-term innovation include a Zhejiang Provincial Research Institute and a provincial enterprise technology center, designed to foster translational research, formulation development, and process optimization.

Operational and innovation priorities that align with the vision:

• Strengthening R&D pipeline via the provincial research institute to accelerate product development cycles.
• Leveraging the enterprise technology center to industrialize novel formulations and improve manufacturing yields.
• Fostering partnerships with universities and contract research organizations to broaden scientific capabilities and regulatory expertise.
• Enhancing quality systems and certifications to meet stringent international regulatory requirements (e.g., GMP standards).

Key performance indicators the company tracks to measure progress toward the vision:

• R&D investment and number of new dossiers filed for registration.
• Market penetration metrics in target export regions and number of regulatory approvals obtained.
• Manufacturing capacity utilization and product quality metrics (batch release success rates, deviation rates).
• Collaborations and technology transfers enabled by the provincial research institute and technology center.

For a deeper look at the company's background, mission, and how it operates within markets, see: Zhejiang Ausun Pharmaceutical Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS) - Vision Statement

• Integrity - honesty and transparency in all business dealings to build trust with partners, patients and regulators.
• Diligence - a relentless work ethic and commitment to operational and clinical excellence across R&D, manufacturing and commercialization.
• Pragmatism - solution-oriented decision-making focused on efficiency, quality and regulatory compliance.
• Innovation - continuous investment in new formulations, generics optimisation and pipeline development to meet evolving medical needs.
• Integrity in Conduct and Work - strict adherence to ethical standards, professional conduct and GxP throughout the value chain.
• Giving Back to Society - CSR through patient access initiatives, community health programs and sustainable corporate practices.

• Advance a balanced portfolio of quality generics, specialty medicines and R&D-driven candidates.
• Strengthen manufacturing capacity with GMP upgrades and digital quality systems to ensure supply continuity.
• Increase R&D productivity through targeted collaborations, clinical partnerships and selective licensing.
• Promote transparent governance, compliance and ESG practices to protect stakeholder trust and long-term growth.

• Integrity: publish regular compliance training completion rates, supplier audits and batch-release transparency metrics.
• Diligence: maintain on-time delivery targets, manufacturing yield rates and product complaint resolution SLAs.
• Pragmatism: use ROI thresholds for portfolio prioritization; streamline product lifecycle decisions by time-to-market KPIs.
• Innovation: monitor number of pipeline candidates, IND/CTA filings, and patent applications per year.
• Integrity in Conduct and Work: track internal ethics incidents, third-party audit results and regulatory inspection outcomes.
• Giving Back to Society: report CSR spend, patient-assistance program reach and community health initiatives annually.